|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pal SK, Nelson RA and Vogelzang N:
Disease-specific survival in de novo metastatic renal cell
carcinoma in the cytokine and targeted therapy era. PLoS One.
8(e63341)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pal SK, Ghate SR, Li N, Swallow E, Peeples
M, Zichlin ML, Perez JR, Agarwal N and Vogelzang NJ: Real-world
survival outcomes and prognostic factors among patients receiving
first targeted therapy for advanced renal cell carcinoma: A
SEER-medicare database analysis. Clin Genitourin Cancer.
15:e573–e582. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Janssen-Heijnen ML, Gondos A, Bray F,
Hakulinen T, Brewster DH, Brenner H and Coebergh JW: Clinical
relevance of conditional survival of cancer patients in Europe:
Age-specific analyses of 13 cancers. J Clin Oncol. 28:2520–2528.
2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pal SK, Vanderwalde A, Hurria A and Figlin
RA: Systemic therapies for metastatic renal cell carcinoma in older
adults. Drugs Aging. 28:635–649. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Miyake H, Aki R, Matsushita Y, Tamura K,
Motoyama D, Ito T, Sugiyama T and Otsuka A: Significance of age in
Japanese patients receiving sunitinib as first-line systemic
therapy for metastatic renal cell carcinoma: Comparative assessment
of efficacy and safety between patients aged <75 and ≥75 years.
Anticancer Res. 38:3593–3599. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus axitinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Motzer RJ, Escudier B, Tomczak P, Hutson
TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J,
Hariharan S, et al: Axitinib versus sorafenib as second-line
treatment for advanced renal cell carcinoma: Overall survival
analysis and updated results from a randomised phase 3 trial.
Lancet Oncol. 14:552–562. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F,
Hora M, Kuczyk MA, et al: European Association of urology
guidelines on renal cell carcinoma: The 2019 Update. Eur Urol.
75:799–810. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
NCCN clinical practice guidelines in
oncology (NCCN guidelines) Kidney Cancer. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
|
|
14
|
Escudier B, Porta C, Bono P, Powles T,
Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins
R, et al: Randomized, controlled, double-blind, cross-over trial
assessing treatment preference for pazopanib versus sunitinib in
patients with metastatic renal cell carcinoma: PISCES Study. J Clin
Oncol. 32:1412–1418. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
De Giorgi U, Scarpi E, Sacco C, Aieta M,
Lo Re G, Sava T, Masini C, De Vincenzo F, Baldazzi V, Camerini A,
et al: Standard vs. adapted sunitinib regimen in elderly patients
with metastatic renal cell cancer: Results from a large
retrospective analysis. Clin Genitourin Cancer. 12:182–189.
2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hutson TE, Bukowski RM, Rini BI, Gore ME,
Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, et al:
Efficacy and safety of sunitinib in elderly patients with
metastatic renal cell carcinoma. Br J Cancer. 110:1125–1132.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Brunello A, Basso U, Sacco C, Sava T, De
Vivo R, Camerini A, Barile C, Roma A, Maruzzo M, Falci C, et al:
Safety and activity of sunitinib in elderly patients (≥70 years)
with metastatic renal cell carcinoma: A multicenter study. Ann
Oncol. 24:336–342. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Poprach A, Lakomy R, Bortlicek Z, Melichar
B, Pavlik T, Slaby O, Vyzula R, Svoboda M, Kiss I, Studentova H, et
al: Efficacy of sunitinib in elderly patients with metastatic renal
cell carcinoma: Data from real-world clinical practice. Drugs
Aging. 33:655–663. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dutcher JP, Tannir N, Bellmunt J and
Escudier B: Experience with sorafenib and the elderly patient. Med
Oncol. 27:1359–1370. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Atkinson BJ, Kalra S, Wang X, Bathala T,
Corn P, Tannir NM and Jonasch E: Clinical outcomes for patients
with metastatic renal cell carcinoma treated with alternative
sunitinib schedules. J Urol. 191:611–618. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Khambati HK, Choueiri TK, Kollmannsberger
CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan
MH, MacKenzie MJ, et al: Efficacy of targeted therapy for
metastatic renal cell carcinoma in the elderly patient population.
Clin Genitourin Cancer. 12:354–358. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Teishima J, Inoue S, Hayashi T and
Matsubara A: Current status of prognostic factors in patients with
metastatic renal cell carcinoma. Int J Urol. 26:608–617.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
De Giorgi U, Procopio G, Giannarelli D,
Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli
P, et al: Association of systemic inflammation index and body mass
index with survival in patients with renal cell cancer treated with
nivolumab. Clin Cancer Res. 25:3839–3846. 2019.PubMed/NCBI View Article : Google Scholar
|
